Mutual Advisors LLC Has $2.47 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Mutual Advisors LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,228 shares of the biopharmaceutical company's stock after buying an additional 3,072 shares during the period. Mutual Advisors LLC's holdings in Gilead Sciences were worth $2,467,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares during the period. Nuveen LLC acquired a new stake in Gilead Sciences during the first quarter worth approximately $620,415,000. Finally, Robeco Institutional Asset Management B.V. grew its stake in Gilead Sciences by 12.5% during the second quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company's stock worth $414,948,000 after purchasing an additional 417,237 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Finally, UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $118.65.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,000 shares of company stock worth $7,986,340 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.4%

GILD stock opened at $117.85 on Friday. Gilead Sciences, Inc. has a twelve month low of $85.60 and a twelve month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock's 50 day moving average is $115.15 and its 200-day moving average is $110.45. The firm has a market capitalization of $146.23 billion, a PE ratio of 23.48, a P/E/G ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the company earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.